Search

Your search keyword '"Aronson, Ronald"' showing total 327 results
Start Over Author "Aronson, Ronald" Search Limiters Academic (Peer-Reviewed) Journals
327 results on '"Aronson, Ronald"'

7. America's Tailspin

Author

Aronson, Ronald

Subjects
The Upswing: How America Came Together a Century Ago and How We Can Do It Again (Nonfiction work) -- Putnam, Robert D. -- Garrett, Shaylyn Romney, Books -- Book reviews, Humanities, Social sciences
Abstract

The Upswing: How America Came Together a Century Ago and How We Can Do It Again Robert D. Putnam, with Shaylyn Romney Garrett New York, NY: Simon & Schuster, 2020. [...]

Published
2021

8. Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.

Author

Perera, Vidya, Abelian, Grigor, Luettgen, Joseph, Aronson, Ronald, Li, Danshi, Wang, Zhaoqing, Zhang, Liping, Lubin, Susan, Merali, Samira, and Murthy, Bindu

Subjects
PRASUGREL, BLOOD platelet aggregation, ASPIRIN, CLOPIDOGREL, PARTIAL thromboplastin time, PHARMACOKINETICS, PLATELET aggregation inhibitors
Abstract

Milvexian, an oral activated Factor XI (FXIa) inhibitor, is in clinical studies where it may be combined with antiplatelet agents, including aspirin and/or clopidogrel, to prevent thromboembolic diseases. This phase I trial assessed safety, pharmacokinetics, and pharmacodynamics of milvexian coadministration with aspirin and/or clopidogrel in healthy participants through 3 drug-drug interaction studies using a 3-period, 3-treatment, crossover design. A total of 113 participants were randomized to receive milvexian (200 mg; twice daily for 5 days) or matched placebo coadministered with once-daily aspirin (325 mg for 5 days) and/or clopidogrel (Day 1: 300 mg; Days 2–5: 75 mg). Milvexian was safe and well tolerated, with and without aspirin and/or clopidogrel. Eight mild bleeding adverse events (AEs) were reported in 5 of 113 participants across various treatment arms. Peak and total exposures of milvexian were similar with or without clopidogrel and/or aspirin. Exposure-dependent prolongation of activated partial thromboplastin time and reduction of FXI clotting activity by milvexian were similar with coadministration of aspirin and/or clopidogrel. Milvexian, with or without coadministration of aspirin and/or clopidogrel, did not affect bleeding time or platelet aggregation. Administration of milvexian alone or with aspirin and/or clopidogrel was safe and well tolerated without increased incidence of AEs, including bleeding. Pharmacokinetic and pharmacodynamic effects of milvexian, including bleeding time, were similar with or without aspirin and/or clopidogrel. ClinicalTrials.gov Identifier: NCT03698513. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial

Author

Hijazi, Ziad, Alexander, John H., Li, Zhuokai, Wojdyla, Daniel M., Mehran, Roxana, Granger, Christopher B., Parkhomenko, Alexander, Bahit, M. Cecilia, Windecker, Stephan, Aronson, Ronald, Berwanger, Otavio, Halvorsen, Sigrun, de Waha-Thiele, Suzanne, Sinnaeve, Peter, Darius, Harald, Storey, Robert F., and Lopes, Renato D.

Published
2021
Full Text
View/download PDF

12. TCT-406 Effect of Antithrombotic Strategies on Total Outcome Events in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS

Author

Tannu, Manasi, primary, Lopes, Renato, additional, Wojdyla, Daniel, additional, Goodman, Shaun, additional, Aronson, Ronald, additional, Mehran, Roxana, additional, Windecker, Stephan, additional, Alexander, John, additional, and Jones, Schuyler, additional

Published
2023
Full Text
View/download PDF

14. Abstract 15664: Prior Oral Anticoagulant Status and Outcomes in Patients With Atrial Fibrillation With an Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the Augustus Trial

Author

Welsh, Robert C, Lopes, Renato D, Wojdyla, Daniel, Aronson, Ronald, Granger, Christopher B, Windecker, Stephan, Vora, Amit, Vinereanu, Dragos, Halvorsen, Sigrun, Parkhomenko, Alexander, Mehran, Roxana, Alexander, John H, and Goodman, Shaun G

Published
2020
Full Text
View/download PDF

18. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial

Author

Windecker, Stephan, Lopes, Renato D., Massaro, Tyler, Jones-Burton, Charlotte, Granger, Christopher B., Aronson, Ronald, Heizer, Gretchen, Goodman, Shaun G., Darius, Harald, Jones, W. Schuyler, Aschermann, Michael, Brieger, David, Cura, Fernando, Engstrøm, Thomas, Fridrich, Viliam, Halvorsen, Sigrun, Huber, Kurt, Kang, Hyun-Jae, Leiva-Pons, Jose L., Lewis, Basil S., Malaga, German, Meneveau, Nicolas, Merkely, Bela, Milicic, Davor, Morais, João, Potpara, Tatjana S., Raev, Dimitar, Sabaté, Manel, de Waha-Thiele, Suzanne, Welsh, Robert C., Xavier, Denis, Mehran, Roxana, and Alexander, John H.

Published
2019
Full Text
View/download PDF

19. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial

Author

Vora, Amit N., Alexander, John H., Wojdyla, Daniel M., Aronson, Ronald, Granger, Christopher B., Darius, Harald, Windecker, Stephan, Mehran, Roxana, Averkov, Oleg, Budaj, Andrzej, Kong, David F., Kobalava, Zhanna, Mehta, Rajendra H., Mirza, Zulfiqar, Guimaraes, Patricia Oliveira, Parkhomenko, Alexander, Quadros, Alexandre, Thiele, Holger, Goodman, Shaun G., and Lopes, Renato D.

Published
2019
Full Text
View/download PDF

24. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke

Author

Bahit, M. Cecilia, primary, Vora, Amit N., additional, Li, Zhuokai, additional, Wojdyla, Daniel M., additional, Thomas, Laine, additional, Goodman, Shaun G., additional, Aronson, Ronald, additional, Jordan, J. Dedrick, additional, Kolls, Brad J., additional, Dombrowski, Keith E., additional, Vinereanu, Dragos, additional, Halvorsen, Sigrun, additional, Berwanger, Otavio, additional, Windecker, Stephan, additional, Mehran, Roxana, additional, Granger, Christopher B., additional, Alexander, John H., additional, and Lopes, Renato D., additional

Published
2022
Full Text
View/download PDF

25. A RANDOMIZED CLINICAL TRIAL OF SCREENING FOR ATRIAL FIBRILLATION WITH A 14-DAY PATCH MONITOR: ANALYSIS OF ECG RECORDINGS FROM THE GUARD-AF STUDY

Author

Singer, Daniel E., primary, Atlas, Steven, additional, Go, Alan S., additional, Lopes, Renato D., additional, Lubitz, Steven, additional, McManus, David, additional, Revkin, James H., additional, Mills, Donna, additional, Crosson, Lori, additional, Lenane, Judith C., additional, and Aronson, Ronald S., additional

Published
2022
Full Text
View/download PDF

26. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial

Author

Welsh, Robert C., primary, Dehghani, Payam, additional, Lopes, Renato, additional, Wojdyla, Daniel M, additional, Aronson, Ronald, additional, Granger, Christopher B, additional, Windecker, Stephan, additional, Vora, Amit N, additional, Vinereanu, Dragos, additional, Halvorsen, Sigrun, additional, Parkhomenko, Alexander, additional, Mehran, Roxana, additional, Alexander, John H, additional, and Goodman, Shaun, additional

Published
2022
Full Text
View/download PDF

28. Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial

Author

Fudim, Marat, primary, Wojdyla, Daniel M., additional, Alexander, John H., additional, Goodman, Shaun G., additional, Mehran, Roxana, additional, Windecker, Stephan, additional, Aronson, Ronald, additional, Vinereanu, Dragos, additional, Halvorsen, Sigrun, additional, Bahit, M. Cecilia, additional, Granger, Christopher B., additional, and Lopes, Renato D., additional

Published
2021
Full Text
View/download PDF

29. Abstract 12512: Antithrombotic Strategies According to Age in Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the Augustus Trial

Author

Guimaraes, Patricia, primary, Lopes, Renato D, additional, Wojdyla, Daniel, additional, Alexander, John H, additional, Goodman, Shaun G, additional, Aronson, Ronald, additional, Halvorsen, Sigrun, additional, Sinnaeve, Peter R, additional, Vinereanu, Dragos, additional, Storey, Robert F, additional, Berwanger, Otavio B, additional, Windecker, Stephan, additional, Mehran, Roxana, additional, Granger, Christopher, additional, and Alexander, Karen P, additional

Published
2021
Full Text
View/download PDF

33. EFFECT OF APIXABAN VERSUS VITAMIN K ANTAGONIST AND ASPIRIN VERSUS PLACEBO ON DAYS ALIVE AND OUT OF HOSPITAL IN THE AUGUSTUS RANDOMIZED CONTROLLED TRIAL

Author

Fanaroff, Alexander C., primary, Vora, Amit, additional, Wojdyla, Daniel, additional, Mehran, Roxana, additional, Granger, Christopher, additional, Goodman, Shaun, additional, Aronson, Ronald, additional, Windecker, Stephan, additional, Alexander, John, additional, and Lopes, Renato, additional

Published
2021
Full Text
View/download PDF

34. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention : Insights From the AUGUSTUS Trial

Author

Hijazi, Ziad, Alexander, John H., Li, Zhuokai, Wojdyla, Daniel M., Mehran, Roxana, Granger, Christopher B., Parkhomenko, Alexander, Bahit, M. Cecilia, Windecker, Stephan, Aronson, Ronald, Berwanger, Otavio, Halvorsen, Sigrun, De Waha-Thiele, Suzanne, Sinnaeve, Peter, Darius, Harald, Storey, Robert F., Lopes, Renato D., Hijazi, Ziad, Alexander, John H., Li, Zhuokai, Wojdyla, Daniel M., Mehran, Roxana, Granger, Christopher B., Parkhomenko, Alexander, Bahit, M. Cecilia, Windecker, Stephan, Aronson, Ronald, Berwanger, Otavio, Halvorsen, Sigrun, De Waha-Thiele, Suzanne, Sinnaeve, Peter, Darius, Harald, Storey, Robert F., and Lopes, Renato D.

Abstract

Background: In the AUGUSTUS trial (An Open-Label, 2x2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), apixaban resulted in less bleeding and fewer hospitalizations than vitamin K antagonists, and aspirin caused more bleeding than placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention treated with a P2Y(12) inhibitor. We evaluated the risk-benefit balance of antithrombotic therapy according to kidney function. Methods: In 4456 patients, the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula was used to calculate baseline estimated glomerular filtration rate (eGFR). The effect of apixaban versus vitamin K antagonists and aspirin versus placebo was assessed across kidney function categories by using Cox models. The primary outcome was International Society on Thrombosis and Haemostasis major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and ischemic events (death, stroke, myocardial infarction, stent thrombosis [definite or probable], or urgent revascularization). Creatinine clearance Results: Overall, 30%, 52%, and 19% had an eGFR of >80, >50 to 80, and 30 to 50 mL.min(-1).1.73 m(-2), respectively. At the 6-month follow-up, a total of 543 primary outcomes of bleeding, 1125 death or hospitalizations, and 282 ischemic events occurred. Compared with vitamin K antagonists, patients assigned apixaban had lower rates for all 3 outcomes across most eGFR categories without significant interaction. The absolute risk reduction with apixaban was most pronounced in those with an eGFR of 30 to 50 mL.min(-1).1.73 m(-2) for bleeding events with rates of 13.1% versus 21.3% (hazard ratio, 0.59; 95% CI, 0.41-0.84). Patients assigned aspirin had a higher risk o

Published
2021
Full Text
View/download PDF

35. Living without God: reply to comments

Author

Aronson, Ronald

Subjects
Atheism -- Study and teaching, Existentialism -- Study and teaching, Philosophers -- Works -- Criticism and interpretation -- Study and teaching, Literature/writing, Philosophy and religion
Abstract

Not believing in God is, on the one hand, a very simple matter. As most Danes and Swedes know, it is increasingly possible to grow up in a wholly secular [...]

Published
2010
Full Text
View/download PDF

36. Celebrating the Critique's fiftieth anniversary

Author

Aronson, Ronald

Subjects
Critique of Dialectical Reason (Nonfiction work) -- Influence -- Criticism and interpretation -- Rites, ceremonies and celebrations -- History, Dialectic -- Study and teaching -- History -- Influence -- Rites, ceremonies and celebrations, Philosophers -- Works -- Criticism and interpretation -- Rites, ceremonies and celebrations -- Study and teaching, Literature/writing, Philosophy and religion
Abstract

ABSTRACT: When published, Sartre's Critique of Dialectical Reason appeared to be a major intellectual and political event, no less than a Kantian effort to found Marxism, with far-reaching theoretical and [...]

Published
2010
Full Text
View/download PDF

37. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention

Author

Hijazi, Ziad, primary, Alexander, John H., additional, Li, Zhuokai, additional, Wojdyla, Daniel M., additional, Mehran, Roxana, additional, Granger, Christopher B., additional, Parkhomenko, Alexander, additional, Bahit, M. Cecilia, additional, Windecker, Stephan, additional, Aronson, Ronald, additional, Berwanger, Otavio, additional, Halvorsen, Sigrun, additional, de Waha-Thiele, Suzanne, additional, Sinnaeve, Peter, additional, Darius, Harald, additional, Storey, Robert F., additional, and Lopes, Renato D., additional

Published
2021
Full Text
View/download PDF

38. Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial

Author

Lopes, Renato D, Leonardi, Sergio, Wojdyla, Daniel M, Vora, Amit N, Thomas, Laine, Storey, Robert F, Vinereanu, Dragos, Granger, Christopher B, Goodman, Shaun G, Aronson, Ronald, Windecker, Stephan, Thiele, Holger, Valgimigli, Marco, Mehran, Roxana, Alexander, John H, University of Zurich, and Lopes, Renato D

Subjects
2737 Physiology (medical), 610 Medicine & health, cardiovascular diseases, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine
Abstract

We describe the incidence, timing, and characteristics of stent thrombosis and its consequences in patients with atrial fibrillation (AF) in the AUGUSTUS trial1 who received a coronary stent during their qualifying admission (acute coronary syndrome [ACS] or elective percutaneous coronary intervention [PCI]) and the randomized treatment effects of low-dose aspirin (compared with placebo) and apixaban (compared with vitamin K antagonist [VKA]) on the risk of stent thrombosis. We included patients who received a stent during their qualifying admission. We excluded patients with medically-managed ACS (n=1097) or an unknown qualifying index event (n=19). The protocol was approved by appropriate ethics committees; patients provided written informed consent prior to participation.

Published
2020
Full Text
View/download PDF

39. How the Irresolvable Camus-Sartre Conflict Helps Us Appreciate the George Floyd Uprising, and Vice-Versa

Author

Aronson , Ronald

Abstract

The Black Lives Matter uprising in the United States that exploded onto the scene after the police killing of George Floyd in May 2020 marks an historic breakthrough – because of its geographic spread throughout the country, its sweeping demand for an end to all racist practices, its willingness to challenge institutions, symbols, and attitudes as well as behaviors, the participation together of millions of Americans of all colors, and especially the involvement of young people. Jean-Paul Sartre and Albert Camus have left us moral and political insights that throw light on this moment: Sartre for his intransigent radicalism and opposition to oppression, Camus for his deep commitment to solidarity and restraint. In their lifetime these sets of attitudes became opposed, and led to their dramatic break. However, today’s uprising has rejected the either/or that split apart the friendship as well as their Cold-War generation. But today, going beyond the Camus/Sartre break, solidarity and restraint have been at the core of the Black Lives Matter uprising, from the start together with a deep commitment to radical change., Studi Sartriani – XIV/2020 – Sartre e l’esistenzialismo americano

Published
2020
Full Text
View/download PDF

40. Camus versus Sartre: the unresolved conflict

Author

Aronson, Ronald

Subjects
Political violence -- Analysis, Literature/writing, Philosophy and religion, Political activity, Criticism and interpretation, Analysis
Abstract

By what incredible foresight did the most significant intellectual quarrel of the twentieth century anticipate the major issue of the twenty-first? When Camus and Sartre parted ways in 1952, the [...]

Published
2005

44. The third man in the story: Ronald Aronson discusses the Sartre-Camus conflict with Francis Jeanson

Author

Aronson, Ronald, Jumel, Caroline, and Kingstone, Basil

Subjects
Camus, Albert -- Biography -- Interviews, Sartre, Jean-Paul -- Interviews -- Biography, Authors, French -- Personal narratives -- History -- 1950s (Decade) AD -- Biography -- Interviews, French literature -- Personal narratives -- History -- 1950s (Decade) AD, Literary quarrels -- 1950s (Decade) AD -- Personal narratives, Literature/writing, Philosophy and religion, History, Personal narratives
Abstract

For over fifty years Francis Jeanson has been one of the world's exemplary radical thinkers and actors. We Sartreans know him as the author of one of the earliest, and [...]

Published
2002

45. Sartre, Camus, and the Caliban articles

Author

Aronson, Ronald

Subjects
Caliban (Periodical) -- History, Philosophy, French -- History -- 1948 AD, Authors, French -- History -- 1948 AD, Democracy -- 1948 AD -- France, Literature/writing, Philosophy and religion, Criticism and interpretation, History
Abstract

In October and November, 1948, an exchange on democracy between Jean-Paul Sartre and Albert Camus appeared in Jean Daniel's monthly Caliban. Except for comments made six months apart in different [...]

Published
2001

48. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial

Author

Vora, Amit N, Alexander, John H, Wojdyla, Daniel M, Aronson, Ronald, Granger, Christopher B, Darius, Harald, Windecker, Stephan, Mehran, Roxana, Averkov, Oleg, Budaj, Andrzej, Kong, David F, Kobalava, Zhanna, Mehta, Rajendra H, Mirza, Zulfiqar, Guimaraes, Patricia Oliveira, Parkhomenko, Alexander, Quadros, Alexandre, Thiele, Holger, Goodman, Shaun G, and Lopes, Renato D

Subjects
610 Medicine & health
Published
2019
Full Text
View/download PDF

49. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Author

Lopes, Renato D, Heizer, Gretchen, Aronson, Ronald, Vora, Amit N, Massaro, Tyler, Mehran, Roxana, Goodman, Shaun G, Windecker, Stephan, Darius, Harald, Li, Jia, Averkov, Oleg, Bahit, M Cecilia, Berwanger, Otavio, Budaj, Andrzej, Hijazi, Ziad, Parkhomenko, Alexander, Sinnaeve, Peter, Storey, Robert F, Thiele, Holger, Vinereanu, Dragos, Granger, Christopher B, and Alexander, John H

Subjects
610 Medicine & health
Abstract

BACKGROUND Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. RESULTS Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results